GSK has more mixed PhIII Relovair data for COPD, but submissions remain on track
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and its partner Theravance have put forward additional mixed Phase III top-line data for once-daily Relovair, a drug containing fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2 agonist (LABA) - this time in two non-pivotal trials for treatment of chronic obstructive pulmonary disease (COPD).